Carruba M O, Ferrari P, Rossi A C, Mantegazza P
Pharmacol Res Commun. 1983 Apr;15(4):367-75. doi: 10.1016/s0031-6989(83)80046-0.
Equiactive antihypertensive doses of clonidine, alpha-methyldopa, hydralazine, propranolol and of a novel compound 355-1057 were tested in an experimental model in which sexual activity was stimulated pharmacologically by lisuride. It was found that those antihypertensive drugs known to cause disturbances in sexual function in men, i.e., clonidine, alpha-methyldopa, hydralazine and propranolol, inhibited lisuride-induced mounting behaviour in male rats, as measured by a decrease in the percentage of animals mounting or in the number of mounts per active animal. The novel antihypertensive compound 355-1057, that seemed in preliminary clinical trials to be devoid of sexual side-effects in men, had no significant effect on the mounting behaviour. It seems, therefore, that the present experimental model could be predictive for antihypertensive drug-induced sexual side-effects in man.
在一个实验模型中，用利舒脲药理刺激性行为，测试了可乐定、α-甲基多巴、肼屈嗪、普萘洛尔和一种新型化合物355 - 1057的等效降压剂量。结果发现，那些已知会导致男性性功能障碍的降压药，即可乐定、α-甲基多巴、肼屈嗪和普萘洛尔，抑制了雄性大鼠中利舒脲诱导的爬跨行为，这通过爬跨动物百分比的降低或每只活跃动物的爬跨次数的减少来衡量。新型降压化合物355 - 1057在初步临床试验中似乎对男性没有性副作用，对爬跨行为没有显著影响。因此，目前的实验模型似乎可以预测降压药对人类的性副作用。
